Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
14.50
+0.06 (+0.42%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report With Tokyo Stock Exchange (TSE) in Line With Revised Corporate Governance Code and Published Corporate Governance Related Documents on its Website
November 01, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Acquisition of Own Shares
October 28, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands
October 28, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Timeless Values, Life-Changing Progress
June 30, 2021
SOURCE: Takeda
Via
3BL Media
Our Planet Commitment
June 15, 2021
SOURCE: Takeda
Via
3BL Media
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
October 27, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
BioLife Plasma Services Announces Expansion of Plasma Donation Centers into Massachusetts
October 13, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
October 07, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Provides Update on TAK-994 Clinical Program
October 05, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
September 30, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
September 22, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
September 21, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
September 15, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
September 01, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
BioLife Plasma Services Opens First All-Electric Plasma Donation Center
August 18, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks
August 05, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie
August 01, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress
July 30, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
July 29, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)
July 28, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders
July 20, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces the Submission of Its Corporate Governance Report to the Tokyo Stock Exchange
July 19, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
July 10, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020
June 29, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Blueprint for Access to Innovative Healthcare Episode 2: Screening
June 17, 2021
SOURCE: Takeda
Via
3BL Media
Blueprint for Access to Innovative Healthcare Episode 1: Awareness and Prevention
June 10, 2021
SOURCE: Takeda
Via
3BL Media
Global Diversity, Equity, and Inclusion Week at Takeda
June 08, 2021
SOURCE: Takeda
Via
3BL Media
Phase 3 Clinical Trial Subgroup Analysis Across Solid Organ Transplant (SOT) Types Supports Efficacy of Maribavir Over Conventional Therapies in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
June 07, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
May 22, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment
May 21, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.